ArticleJournal of fungi (Basel, Switzerland)2023
CRISPR-Cas9 Gene Editing and Secondary Metabolite Screening Confirm
Article in Journal of fungi (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- A streamlined protocol for small-scale protoplast generation and CRISPR/Cpf1-mediated genome editing iniScience · 2026Article
- An ABC-B Transporter Helps ProtectJournal of fungi (Basel, Switzerland) · 2026Article
- 2-Hydroxy-4-Methoxybenzaldehyde (2H4MB): Integrating Cell Culture, Metabolic Engineering, and Intelligent Genome Editing.International journal of molecular sciences · 2026Review
- Discovery of Fusadapamides, Accessory Chromosome-Associated Metabolites Incorporating l-2,3-Diaminopropionic Acid inJournal of natural products · 2025Article
- Comparative transcriptomics reveal contrasting strategies between a fungal plant pathogen and an endophyte during initial host colonization.Microbiology spectrum · 2025Article
- Identification and Confirmation of Virulence Factor Production fromJournal of fungi (Basel, Switzerland) · 2024Article
- Unlocking Fungal Potential: The CRISPR-Cas System as a Strategy for Secondary Metabolite Discovery.Journal of fungi (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.